SCHEMBL4313384

SCHEMBL4313384

COCCCNCc1ccc(/C=C/c2n[nH]c3ccccc23)c(NC(=O)c2sccc2C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 4/20 0.57
▸ AURKB Q96GD4 3/20 0.57
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SMN1; SMN2 Q16637 5/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ KDR P35968 3/20 0.36
▸ HPGD P15428 1/20 0.36
▸ CASP3 P42574 1/20 0.35
▸ SENP8 Q96LD8 1/20 0.35
▸ SENP7 Q9BQF6 1/20 0.35
▸ SENP6 Q9GZR1 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313397 1.00 AURKA (0.57) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4317617 0.89 AURKA (0.58) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4317606 0.89 AURKA (0.58) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4312994 0.88 AURKA (0.62) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4312987 0.88 AURKA (0.62) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4313400 0.86 AURKA (0.58) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4313389 0.86 AURKA (0.58) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL31824 0.86 AURKA (0.66) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4313957 0.86 AURKA (0.66) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4322655 0.85 AURKA (0.69) AURKAAURKBNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 — — EP claimed
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 — — EP disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885NPC1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback